Publications by authors named "A Salvatore"
Background: Hemorrhoidal disease (HD) is associated with substantial economic burden and negative effects on health-related quality of life (HRQoL). The aCute HaemORrhoids treatment with MESoglycan (CHORMES) study aims to evaluate the effects of orally administered mesoglycan, a natural preparation of glycosaminoglycans with antithrombotic and profibrinolytic properties, as an acute treatment in patients with HD.
Methods: CHORMES is a phase 2, double-blind, randomized controlled trial being conducted at two centers in Italy.
Background: To date, there has been no medication that has prevented the progression of Parkinson's disease (PD). Many benefits of intensive and multidisciplinary rehabilitation program for PD are supported by clinical, epidemiological, and experimental data. The main question is whether high-intensity motor and cognitive exercises have an effect on the disease's biological mechanisms.
View Article and Find Full Text PDFArticle Synopsis
- The study aimed to evaluate the effectiveness of using ketamine along with midazolam for treating refractory and super-refractory status epilepticus compared to using midazolam alone.
- Researchers analyzed data from a neurointensive care unit, identifying two groups of patients: one receiving only midazolam (MDZ cohort) and the other receiving a combination of midazolam and ketamine (Ket+MDZ cohort).
- Results indicated that while the overall time from midazolam start to seizure end was similar for both groups, the Ket+MDZ cohort experienced a significantly shorter time from the start of ketamine infusion to seizure end, suggesting that ketamine may enhance treatment efficacy.
Introduction: The Janus kinase (JAK) family includes four cytoplasmic tyrosine kinases (JAK1, JAK2, JAK3, and TYK2) constitutively bound to several cytokine receptors. JAKs phosphorylate downstream signal transducers and activators of transcription (STAT). JAK-STAT5 pathways play a critical role in basophil and mast cell activation.
View Article and Find Full Text PDFArticle Synopsis
- Nivolumab combined with relatlimab and ipilimumab has been approved for treating advanced melanoma based on clinical trials, but no direct comparison of the two treatments existed, leading to an indirect comparison using patient-level data.
- The study utilized inverse probability of treatment weighting to balance patient characteristics and compared various outcomes like progression-free survival and treatment-related adverse events, finding both regimens had similar efficacy.
- Nivolumab plus relatlimab showed a better safety profile, with fewer severe side effects and treatment discontinuations than nivolumab plus ipilimumab, although some subgroup analyses suggested varying results.